27
Overview • - Indirect cholinergic agonism (AchE inhibition) • - Muscarinic antagonism (emphasis on drugs and organ effects) • - Nicotine-Ach receptor (emphasis on drugs and therapeutics)

lecture-2

Embed Size (px)

DESCRIPTION

jhj

Citation preview

  • Overview- Indirect cholinergic agonism (AchE inhibition)

    - Muscarinic antagonism (emphasis on drugs and organ effects)

    - Nicotine-Ach receptor (emphasis on drugs and therapeutics)

  • Indirect cholinergic agonistsInhibitors of acetylcholinesterase

    Increase acetylcholine concentration and lifetime by inhibiting degradation

    Act by binding to AchE active site causing reversible(non covalent) or long lasting (covalent modification)

  • Mechanisms of indirect agonism- Quaternary alcohols (ephodronium) reversible binding (limit acetylcholine access)

    Non covalent enzyme-inhibitor complex lifetime (2 - 10 minutes)

    Carbamate esters neostigmine, physostigmine reaction with AchE active site

    Covalent carbamoylation enzyme-inhibitor complex lifetime (0.5 - 6h)

    Organophosphates Parathion, Sarin, Soman - phophorylates AchE active site

    Covalent phosphorylation very stable enzyme-inhibitor complex, days (especially after aging)

  • AchE Inhibitors (quaternary alcohols and carbamates)

  • Organophosphates

  • Aging

  • Organ effects/therapeutic uses- Effects are due to acetylcholine accumulation and are both sympathetic and parasympatheticUSESApprox DurationALCOHOLS

    Edrophonium Myasthenia gravis5 15 minutesarrythmias

    CARBAMATES

    NeostigmineMyasthenia gravis0.5 2hPyridostigmineMyasthenia gravis3 6hPhysostigmineGlaucoma0.5 2hDemecarium Glaucoma4 6h

    Organophosphates

    EchotiophateGlaucoma100 h (> 4 days)

  • Treatment of organophosphate poisoning1 - maintenance of vital signs (respiration particularly important)

    2 - Decontamination (to avoid further absorption)

    3 - Atropine parenterally (to minimize muscarinic effects) as required

    4 - Rescue of AchE activity with Hydroxylamines (Pralidoxime, Diacetylmonoxime)

  • Muscarinic antagonismAttropa belladona

  • Muscarinic AntagonistsATROPINESCOPOLAMINE

  • Muscarinic AntagonistsATROPINESCOPOLAMINEAttropa belladona Atropine and Scopolamine are belladona alkaloids (competitive inhibitors)

    Drugs differ in their CNS effects, scopolamine permeates the blood-brain barrier

    At therapeutic doses atropine has negligible effects upon the CNS, scopolamine even at low doses has prominent CNS effects.

  • Mechanism of drug actionCompetitively block muscarinic receptors

    - Salivary, bronchial, and sweat glands aremost sensitive to atropine

    - Smooth muscle and heart are intermediatein responsiveness

    In the eye, causes pupil dilation and difficulty for far vision accomodation

    Relaxation of the GI, slows peristalsis

  • History/sourcesAtropa belladona - used in the renaissanceDeadly nightshade - used in the middle ages to produce prolonged poisoning

    Jimson plant leaves burned in India to treat Asthma (1800) purification of atropine (1831)

  • Effect of muscarinic inhibitor in the eyePupil dilation vs accomodation

  • Effect of muscarinic inhibition in the heart and salivary glands Increases the heart rate after a transient bradychardia at the low dose Diminishes gland excretory function

  • Graphic summary of atropine effects

  • Organ effect drug reviewAntidotesORGAN DRUGAPPLICATIONCNS Benztropine Treat Parkinsons disease Scopolamine Prevent/Reduce motion sickness

    Eye Atropine Pupil dilation

    Bronchi IpatropiumBronchodilate in Asthma, COPD

    GI MethscopolamineReduce motility/crampsGU OxybutininTreat transient cystitisPostoperative bladder spasms

  • Toxicity of muscarinic antagonistsDRY AS BONE, RED AS A BEET, MAD AS HATTER.

    Dry is a consequence of decreased sweating, salivation and lacrimation

    Red is a result of reflex peripheral (cutaneous) vasodilation to dissipate heat (hyperthermia)

    Mad is a result of the CNS effects of muscarinic inhibition which can lead to sedation, amnesia (hypersensitivity), or hallucination

  • Nicotinic Acetylcholine Receptor polarizedRelaxation depolarizedcontraction

  • Signaling through Ach-nicotinic receptor(competitive and depolarizing blockers)

  • Competitive/depolarizingCompetitivePhysically blocks Ach bindingINHIBITOR

  • Examples of competitive/depolarizing drugsCompetitiveTubocurarineMivacuriumDepolarizingAchEButyrylcholinesteraseSensitive sitesSuccinylcholine

  • Clinical usesAdjuvant use in surgical anesthesia (muscular relaxation)

    Advantage much lighter levels of anesthesia required

    Other uses: muscular relaxation for orthopedics (correction of dislocation/alignment of fractures)

    (short duration) facilitate intubation, laryngoscopy, bronchoscopy, esophagoscopy

    Control of muscular spasms, strabism, hemifacial spasms, oromandibular and cervical dystonia, spasms of the lower esophageal sphincter

    Cosmetic Bottox (Botulinum toxin A)

    Paralytic action on skeletal muscle

  • Agents/Features/DurationAGENT CLASS PROPERTY ONSET DURATION Succinylcholine Dicholine ester Depolarization 1 min 5 8 min

    Tubocurarine Alkaloid Competitive 5 min 80 120 min

    Atracurium BenzylisoquinolineCompetitive 3 min 30 60 min

    Mivacurium Benzylisoquinoline Competitive 3 min 12 18 min

    Pancuronium Ammonio SteroidCompetitive 5 min 120 180 min

    Vecuronium Ammonio SteroidCompetitive 3 min 60 90 min

    Hydrolysis by esterasesLiver clearance/renal eliminationBoth

  • Precautions/Toxicity- Prolonged apnea, cardiovascular collapse

    Sequence of paralysis : Eye muscles, Jaw, Larynx, limbs and trunk, intercostal muscles and the dyaphragm

    Generally caused by diminished esterase activity, renal malfunction, liver insufficiency, poor circulatory function.

    Special caution in patients with electrolyte imbalance (K+)

    Antidote : Neostigmine/Ephodronium to increase Ach, and atropine to block Ach muscarinic stimulation.

    Malignant hyperthermia results from a discharge of Ca2+, exacerbated muscular action tachycardia, hyperthermia, acidosis and rigidity (mutations of RYR1, central core disease) treated with Dantrolene, preservation of respiration

  • SummaryXTetrodoxinBatrachotoxinXHemicholiniumBotulinum toxinXCurare alkaloidsSnake venom XAchHydrolysisAchE inhibitorsXDantroleneAchpilocarpineMuscarineBethanecholNeostigmine**Edrophonium**

    X** IndirectAtropineScopolamineTubocurarineMivacurium

  • Moviehttp://www.youtube.com/watch?v=yd46Hs7pTowNicotine in the brain